Trial results

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

NCT07284979 on ClinicalTrials.gov · last registry update 2026-10-06

An unusually large phase 3: 1,270 participants, more than double the 424 typical for the stage. Due to report March 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: Percent Change From Baseline in Body Weight at Week 76. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Kailera

Sponsor type

Industry

Enrollment

1,270

Started

2025-12-30

Primary completion

2028-03 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percent Change From Baseline in Body Weight at Week 76

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.